EMRO

Morocco

Post-validation survey for the elimination of blinding trachoma to evaluate the effectiveness of a serological surveillance strategy in two provinces of Morocco

Conduct district-wide field trials of the Pgp3 lateral flow assay to measure the seroprevalence of antibodies against the Chlamydia trachomatis antigen Pgp3 in low-prevalence settings.

Countries: Morocco
Diseases: Trachoma

Sudan

Mapping the Potential Risk of Mycetoma Infection in Sudan and South Sudan Using Ecological Niche Modeling

What is the potential distribution of mycetoma in Sudan and South Sudan? What are the most important factors associated with the spatial distriutional patterns of disease cases in Both countries. 

 

Countries: Sudan
Diseases: Mycetoma

Development of a community-based mycetoma early detection programme

Can behavioural change communication lead to earlier presentation of mycetoma in rural Sudan?

Countries: Sudan
Diseases: Mycetoma

Egypt

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Egypt

What is the indicator(s) and accompanying monitoring and evaluation (M&E) strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: Egypt

Saudi Arabia

Insecticide resistance in dengue vectors, Jeddah

Defining the insecticide resistance status of dengue vectors in Jeddah and Makkah; essential prerequisite to developing an effective response in the event of an outbreak in these important sites.

Countries: Saudi Arabia

Evaluation and Control of Cutaneous Leishmaniasis in KSA

Cutaneous Leishmaniasis (CL) is exclusively transmitted by the bite of a female sand fly. In collaboration with the Saudi Arabian Ministry of Health, we have developed a programme aiming to prevent and control CL in this country. The programme focuses, among other aspects, in developing a rapid diagnostic test based on the patient’s anti-alpha-Gal response, and in identifying markers for disease exposure. We recently found evidence that treatment efficacy against Old World CL varies with parasite species, geographical locations and the development of secondary infections. This has implications on the treatment of this debilitating disease. The severity of a leishmaniasis ulcer partly depends on the patient’s previous exposure to sand fly bites. This explains the increased protection against CL in individuals living in CL-endemic areas and supports development of potential vaccine models based on sand fly salivary proteins. Furthermore, Old World CL patients produce high levels of anti-Gal antibodies (i.e. recognise terminal alpha-galactosyl epitopes). This discovery is currently being exploited for the making of rapid diagnostic tools and a potential protective glycovaccine model against CL. We hope that these tools can soon be applied in other CL-endemic countries, including refugee settings.

Countries: Saudi Arabia
Diseases: Leishmaniasis